Source study found

Story checked

New immune profiling tool identifies antibodies that trigger preterm births (opens in a new tab)

news-medical.net · 2026-10-14

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

One claim goes further than the study. 4 other points were not covered by the paper.

1 supported
1 overstated
4 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail

The story

New immune profiling tool identifies antibodies that trigger preterm births

news-medical.net · 2026-10-14

The story’s checkable claims.

Read the original story

NewsLink checks it

Mostly not supported

One claim overstates the study. One of six checks out. Four claims the study doesn't address.

1 supported
1 overstated
4 not covered

Open claim evidence

The source study

Evidence for Maternal Autoantibodies in the Pathogenesis of Preterm Birth

medRxiv : the Preprint Server for Health Sciences · 2025Open access

Open source record Open in Tessa

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

Reading mode

Scan verdicts. Open evidence only when needed.

Browse by verdict

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6OverstatedResearchers at UC San Francisco discovered antibodies that play a role in triggering early labor, and the antibodies were present at higher levels and appeared earlier in pregnancy in women who later delivered before 37 weeks than in women who delivered at term.View evidenceHide evidence

As statedabout 1 in 10 pregnancies involve preterm birth; before 37 weeks

Why this verdict

The paper profile supports an association between maternal autoreactivity, including anti-IL1RA in a subset of preterm pregnancies, and preterm delivery, plus in vitro and mouse evidence supporting biological plausibility. But the story's lead says the antibodies 'play a role in triggering early labor' as an unhedged causal claim in humans. At abstract depth, the human evidence is observational and cannot establish that the antibodies trigger human preterm labor. The profile also does not verify the claim that the antibodies appeared earlier in pregnancy.

Study evidence

Preterm pregnancies show greater proteome-wide maternal autoreactivity than term pregnancies across eight cohorts (n=2,194).

“we employ proteome-wide autoantibody profiling via phage display immunoprecipitation and sequencing (PhIP-seq) to identify autoreactivities associated with pregnancy as well as term or preterm delivery outcomes in maternal sera across eight cohorts of human pregnancy (n=2,194)”

Study evidence

Antibodies to IL1 receptor antagonist (IL1RA) are significantly enriched across eight cohorts and are present in roughly 7% of preterm pregnancies.approximately 7% prevalence among preterm pregnancies; reported as statistically significant enrichment across cohorts (exact statistics not provided in abstract)

“Across these eight cohorts, antibodies to cytokine IL1 receptor antagonist (IL1RA) ... are significantly enriched in roughly 7% of preterm pregnancies.”

Claim 2 of 6Not coveredThe work was published in Nature Immunology and used a new immune profiling tool built at UCSF, called PhIP-Seq, to identify a set of antibodies that appeared consistently once pregnancy began.View evidenceHide evidence

As statedmore than 2,000 pregnant women across eight cohorts

Why this verdict

The abstract-level profile supports use of PhIP-seq across eight cohorts totaling n=2,194 to identify autoreactivities associated with pregnancy and term versus preterm outcomes. However, the profile does not verify the publication venue, that PhIP-seq was a new UCSF-built tool, the quoted statement, or the more specific framing that a set of antibodies appeared consistently once pregnancy began.

Study evidence

Preterm pregnancies show greater proteome-wide maternal autoreactivity than term pregnancies across eight cohorts (n=2,194).

“we employ proteome-wide autoantibody profiling via phage display immunoprecipitation and sequencing (PhIP-seq) to identify autoreactivities associated with pregnancy as well as term or preterm delivery outcomes in maternal sera across eight cohorts of human pregnancy (n=2,194)”

Claim 3 of 6Not coveredWhen the researchers injected IL-1RA antibodies into pregnant mice, IL-1β levels rose in the mothers' blood and their placentas showed signs of damage, which the article says was also seen in human preterm deliveries.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that anti-IL1RA exposure in timed-pregnant mice increased resorption, inflammation, and vascular malperfusion. It does not verify the more specific story details that IL1β levels rose in the mothers' blood, that the antibodies were injected, or that the same placental damage pattern was shown in human preterm deliveries.

Study evidence

Administration/exposure to anti-IL1RA in timed-pregnant mice increased fetal resorption and caused greater inflammation and placental vascular malperfusion.

“anti-IL1RA induces greater resorption, inflammation, and vascular malperfusion in timed-pregnant mice in vivo.”

Claim 4 of 6Not coveredThe article says the findings suggest anakinra, a synthetic IL-1RA drug already used for inflammatory disease, could be worth investigating as a way to prevent preterm birth.View evidenceHide evidence

As statednearly two decades of safety data

Why this verdict

The paper profile supports a general therapeutic implication: interventions to restore control of IL1β during pregnancy might be useful. But the abstract-level profile does not mention anakinra specifically, does not describe it as an already-approved synthetic IL1RA drug, and does not verify the 'nearly two decades of safety data' statement.

Study evidence

“Across these eight cohorts, antibodies to cytokine IL1 receptor antagonist (IL1RA) ... are significantly enriched in roughly 7% of preterm pregnancies.”

Study evidence

Administration/exposure to anti-IL1RA in timed-pregnant mice increased fetal resorption and caused greater inflammation and placental vascular malperfusion.

“anti-IL1RA induces greater resorption, inflammation, and vascular malperfusion in timed-pregnant mice in vivo.”

Claim 5 of 6Not coveredThe researchers caution that the anti-IL-1RA antibodies were seen in only a fraction of preterm births, and they do not yet know whether the antibodies were present before pregnancy or arose after conception.View evidenceHide evidence

As statedonly a fraction of preterm births

Why this verdict

The profile supports that anti-IL1RA antibodies were found in only a subset of preterm pregnancies, approximately 7%. However, the abstract-level profile does not verify the specific caution that researchers do not know whether the antibodies were present before pregnancy or arose after conception.

Study evidence

“Across these eight cohorts, antibodies to cytokine IL1 receptor antagonist (IL1RA) ... are significantly enriched in roughly 7% of preterm pregnancies.”

Claim 6 of 6SupportedWithin the antibody signature, an antibody against IL-1RA stood out; the article says IL-1RA normally helps block IL-1β-driven inflammation, so neutralizing it could allow inflammation and uterine contractions to rise unchecked.View evidenceHide evidence

Why this verdict

The paper profile supports that anti-IL1RA antibodies were significantly enriched in a subset of preterm pregnancies, that patient sera with anti-IL1RA neutralized IL1RA activity in vitro, and that the IL1β inflammatory cascade was implicated. The story's mechanistic language is hedged as 'could,' which is broadly consistent with the abstract-level evidence, though human causality is not established.

Study evidence

“Across these eight cohorts, antibodies to cytokine IL1 receptor antagonist (IL1RA) ... are significantly enriched in roughly 7% of preterm pregnancies.”

Study evidence

Sera from anti-IL1RA–positive patients functionally neutralize IL1RA activity in vitro.

“Sera from these patients functionally neutralize IL1RA activity in vitro”

Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

The human cohort evidence is observational and cannot by itself establish that autoantibodies cause or trigger human preterm labor.
The story includes some caveats about subset prevalence and timing, but the lead frames the antibodies as triggering early labor. It does not clearly state the key limitation that the human evidence is observational and causality in humans is not established.
From Observational multi-cohort maternal serology profiling (PhIP-seq); cohort-based serologic association (PhIP-seq)
Patient sera with anti-IL1RA functionally neutralized IL1RA activity in vitro.
The story discusses the proposed consequence of neutralizing IL1RA, but the presented claims do not explicitly report the paper's in vitro patient-sera neutralization experiment.
From in vitro neutralization assay
Mouse-model findings support pathogenic potential but do not establish causation or treatment efficacy in humans.
The story uses the mouse experiment to support a causal biological narrative but, as presented, does not clearly convey the limitation that animal pregnancy findings may not translate directly to human preterm birth.
From timed-pregnant mouse in vivo antibody exposure
Placental proteome immunoprecipitation–mass spectrometry using patient sera provided orthogonal ex vivo validation of increased autoreactivity.
The story claims do not mention the placental proteome IP-MS validation experiment, which is a distinct secondary component in the paper profile.
From placental proteome IP‑MS validation
The abstract does not report quantitative effect sizes, confidence intervals, p-values, cohort-specific results, or confounder-adjustment details.
The story does not mention the limited statistical detail available at abstract depth. This is material because the story presents some findings prominently and causally despite the profile lacking detailed human effect estimates or adjustment information.
From Observational multi-cohort maternal serology profiling (PhIP-seq); cohort-based serologic association (PhIP-seq); timed-

4 things the story did carry across

Proteome-wide PhIP-seq profiling across eight human pregnancy cohorts, n=2,194, found greater overall maternal autoreactivity in preterm pregnancies than term pregnancies.
Anti-IL1RA autoantibodies were significantly enriched in only a subset of preterm pregnancies, roughly 7%.
Anti-IL1RA exposure in timed-pregnant mice increased fetal resorption, inflammation, and vascular malperfusion.
The authors suggest possible serologic risk stratification and therapeutic strategies to restore IL1β control during pregnancy.

Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoProteome-wide maternal autoantibody profiling across eight pregnancy cohorts identifies autoreactivities associated with pregnancy and with term vs preterm delivery; preterm pregnancies show greater proteome-wide autoreactivity and pathway enrichment.Observational multi-cohort maternal serology profiling (PhIP-seq)Expand

In plain English

Proteome-wide autoantibody profiling (PhIP-seq) of maternal sera across eight pregnancy cohorts (n=2,194) identified greater overall autoreactivity in pregnancies that ended preterm compared with term. The preterm-associated autoreactive signature was enriched for pathways relevant to pregnancy (vascular development, reproductive hormones, inflammatory regulators) and implicated the IL1β cytokine cascade. Antibodies to the IL1 receptor antagonist (IL1RA) were reported as significantly enriched in ~7% of preterm pregnancies; these sera neutralized IL1RA in vitro and anti-IL1RA exposure produced increased fetal resorption, inflammation, and vascular malperfusion in timed-pregnant mice. The authors propose potential utility of serologic diagnostics to stratify spontaneous preterm delivery risk and therapeutic strategies to restore control of IL1β during pregnancy.

Key findings

Preterm pregnancies show greater proteome-wide maternal autoreactivity than term pregnancies across eight cohorts (n=2,194).
The preterm-associated autoreactive signature is enriched for pathways important to pregnancy, including vascular development, reproductive hormone pathways, and regulators of inflammation.

“we employ proteome-wide autoantibody profiling via phage display immunoprecipitation and sequencing (PhIP-seq) to identify autoreactivities associated with pregnancy as well as term or preterm delivery outcomes in maternal sera across eight cohorts of human pregnancy (n=2,194)”

What this piece can’t prove

Abstract does not report effect sizes, confidence intervals, p-values, cohort-specific results, or methods for confounder control and adjustment.
Observational cohort associations cannot by themselves establish causality between autoantibodies and preterm birth.

2 further details could not be confirmed from the summary.

2ex vivo humanPlacental proteome immunoprecipitation–mass spectrometry using patient sera validates the increased autoreactivity signal observed in PhIP-seq.placental proteome IP‑MS validationExpand

In plain English

An orthogonal ex vivo validation using patient sera and placental proteome immunoprecipitation followed by mass spectrometry (IP‑MS) corroborated the PhIP‑seq observation of greater proteome‑wide autoreactivity in preterm pregnancies.

Key findings

Placental proteome immunoprecipitation–mass spectrometry using patient sera validated the increased proteome‑wide autoreactivity signal observed by PhIP‑seq in preterm pregnancies.

“validated by placental proteome immunoprecipitation mass spectrometry analysis using patient sera.”

What this piece can’t prove

Abstract provides only a brief statement of IP‑MS validation without methodological or quantitative detail (no sample counts, effect estimates, or lists of validated targets).

2 further details could not be confirmed from the summary.

3human in vivoAcross cohorts, anti-IL1RA autoantibodies are significantly enriched in a subset (~7%) of preterm pregnancies, implicating the IL1β inflammatory cytokine cascade.cohort-based serologic association (PhIP-seq)Expand

In plain English

Across eight human pregnancy cohorts (n=2,194), proteome-wide autoantibody profiling (PhIP-seq) identified antibodies targeting the IL‑1 receptor antagonist (IL1RA) that are significantly enriched among preterm pregnancies, with an approximate prevalence of 7% in the preterm group.

Key findings

Antibodies to IL1 receptor antagonist (IL1RA) are significantly enriched across eight cohorts and are present in roughly 7% of preterm pregnancies.approximately 7% prevalence among preterm pregnancies; reported as statistically significant enrichment across cohorts (exact statistics not provided in abstract)

“Across these eight cohorts, antibodies to cytokine IL1 receptor antagonist (IL1RA) ... are significantly enriched in roughly 7% of preterm pregnancies.”

What this piece can’t prove

3 further details could not be confirmed from the summary.

4in vitroPatient sera with anti-IL1RA functionally neutralize IL1RA activity in vitro.in vitro neutralization assayExpand

In plain English

Using patient sera from pregnancies with anti-IL1RA autoreactivity, the authors report that those sera 'functionally neutralize IL1RA activity in vitro.' The abstract does not provide assay details, quantitative effect sizes, or sample-size information for this in vitro neutralization result.

Key findings

Sera from anti-IL1RA–positive patients functionally neutralize IL1RA activity in vitro.

“Sera from these patients functionally neutralize IL1RA activity in vitro”

What this piece can’t prove

3 further details could not be confirmed from the summary.

5in vivo animalIn vivo, anti-IL1RA exposure in timed-pregnant mice increases resorption, inflammation, and vascular malperfusion, supporting pathogenic potential relevant to preterm birth biology.timed-pregnant mouse in vivo antibody exposureExpand

In plain English

In a timed-pregnant mouse in vivo experiment, administration/exposure to anti-IL1RA increased fetal resorption and produced greater inflammation and placental vascular malperfusion; the authors interpret these results as evidence that anti-IL1RA antibodies can have pathogenic effects relevant to preterm birth biology.

Key findings

Administration/exposure to anti-IL1RA in timed-pregnant mice increased fetal resorption and caused greater inflammation and placental vascular malperfusion.